ARTICLE | Clinical News
TP10: Completed Phase IIb trials
September 4, 2001 7:00 AM UTC
Avant Immunotherapeutics Inc. (AVAN), Needham, Mass. Product: TP10 Business: Cardiovascular Therapeutic category: Immune modulation, Membrane attack Target: Complement Description: Soluble form of co...